Articles on Patents

Displaying 1 - 20 of 126 articles

When companies file hundreds of patents for a single drug, affordable versions can remain out of reach for years. pilli/iStock via Getty Images Plus

Some new drugs aren’t actually ‘new’ – pharmaceutical companies exploit patents and raise prices for patients, but data transparency can help protect innovation

By extending their monopoly on a drug, companies prevent generics and other competitors from driving down prices. But increasing transparency can help prevent Big Pharma from gaming the patent system.
Pooling procurement of drugs could increase the availability of essential treatments around the globe. narvo vexar/iStock via Getty Images Plus

When developing countries band together, lifesaving drugs become cheaper and easier to buy − with trade‑offs

Pharmaceutical companies have little incentive to sell drugs to countries that can’t afford them. But bargaining together can increase access to vital treatments worldwide.
Only humans can be awarded patents, but AIs can do a lot of the work to earn them. lineartestpilot/iStock via Getty Images

When humans use AI to earn patents, who is doing the inventing?

US patent law says inventors must be human, but they can use AI. This changes the nature of invention and raises the question: Is this what the founders had in mind when they set up the patent system?
Getty Images

Patently insufficient: a new intellectual property treaty does little to protect Māori traditional knowledge

The newly signed global Treaty on Intellectual Property, Genetic Resources and Traditional Knowledge might improve the patent system, but is unlikely to improve protection of Indigenous knowledge itself.
Government information sources like the U.S. patent database often file bad information without labeling it or providing a way to retract it. Thinglass/iStock via Getty Images

When authoritative sources hold onto bad data: A legal scholar explains the need for government databases to retract information

Theranos was dissolved years ago, and its CEO, Elizabeth Holmes, is in prison, but the company’s patents based on bad science live on – a stark example of the persistence of faulty information.

Top contributors

More